Dr. Reddy's Laboratories announced the launch of Fosaprepitant for Injection, the therapeutic generic equivalent of EMEND
(fosaprepitant) for injection, approved by the U.S. Food and Drug Administration (USFDA).
The EMEND for Injection brand had an U.S. sales of approximately $279 million MAT for the most recent twelve months ending in July 2019 according to IQVIA Health.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
